Answers are grounded in this paper and cite their sources.
Retrospective study reveals foveal reattachment and visual improvement following serial anti-VEGF therapy in proliferative diabetic retinopathy, suggesting an alternative to immediate vitrectomy.
Purpose: To report the outcomes of patients with fovea-off tractional retinal detachment (TRD) from proliferative diabetic retinopathy (PDR) treated with serial anti-VEGF therapy. Methods: We reviewed the medical records of patients with fovea-off TRD from PDR treated with serial anti-VEGF therapy. Outcome measures included visual acuity, foveal reattachment, need for vitrectomy, number of intravitreal injections, and average interval between injections. Results: 12 eyes of 10 patients were included. 75% of eyes (n = 9) had foveal reattachment with anti-VEGF therapy alone. The average time from TRD diagnosis to foveal reattachment was 15 months. Patient who experienced foveal reattachment (n = 9) received an average of 7 injections with an average injection interval of 2.3 months. At presentation, mean logMAR VA was 1.79 (Snellen visual acuity equivalent 20/1233). At 6 months, mean logMAR VA was 1.6 (20/790), and at 12 months, mean logMAR VA was 1.4 (20/466). At a last follow-up (mean 27.8 months), mean logMAR VA was to 1.36 (20/453) among all patients and 1.01 (20/204) among patients who had foveal reattachment. Conclusion: In this cohort of eyes treated with intravitreal anti-VEGF for fovea-off TRD from PDR retinopathy, we observed visual and anatomic stability, and, in some cases, improvement.
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: